Supplementary Figures 1-2, Supplementary Tables 1-2 from p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy

Figure S1: Frequency of Tregs does not significantly decline post treatment and does not correlate with p53-reactivity or PFS.; Figure S2: Frequency of MDSC does not significantly differ to healthy controls, does not decline post treatment and does not correlate with p53-reactivity or PFS.; Supplementary Table T1: Multi variation analysis* shows an association between progression free survival and frequency of p53-reactive T cells, disease stage and baseline MDSC. Supplementary Table T2: Correlations (Pearson) of variables included in multi variation analysis.